Zofran Lawsuit Plaintiffs Point To Study Results Indicating Twofold Increase In Development Of Cleft Palate

February 29, 2016 – – ZofranLegal.com reports on concerning results of several studies which appear to link Zofran exposure to fetuses through their mothers to the development of congenital birth defects in those fetuses. The drug, now a subject of increasing controversy, was developed by corporate giant GlaxoSmithKline, and then, in an especially controversial move, was marketed “off-label” by the company to pregnant women across the nation for a use which the drug was never FDA-approved to treat.

Zofran is an anti-nausea drug which was given approval by the United States Food and Drug Administration (FDA) specifically to treat patients suffering from nausea and vomiting episodes after undergoing chemotherapy, radiation, or anesthesia. After the manufacturer was given this approval, however, GlaxoSmithKline also began to market their drug as a morning sickness treatment, both to Ob/Gyn offices across the nation and to the general public. Plaintiffs currently involved in lawsuits surrounding the drug call that marketing tactic “reckless and negligent”, as the drug had never been tested for safety on pregnant women and their unborn babies, and had never been given FDA approval for this use.

Because of this “off-label” marketing, Zofran was prescribed “off-label” to an estimated 1 million women in just one year’s time. Today, the anti-nausea drug has become the topic of a surge of lawsuits from parents across the nation who all similarly allege that by taking the medication while pregnant, they caused their their growing babies to develop a range of severe, and sometimes fatal, congenital birth defects. Defects most commonly mentioned in Zofran lawsuits are cleft lip and palate, kidney defects, clubfoot, transposition of the greater vessels, tetralogy of fallot, atrial septal defect and ventricular septal defect, and respiratory distress.

Plaintiffs involved in Zofran birth defect lawsuits have gained support from several concerning studies. In 2012, a study highlighted a twofold increase in the likelihood of cleft palate development for fetuses exposed to Zofran while in utero. Another notable study, published in 2014, found that Zofran exposure appeared to cause a 30% overall increased risk for the development of congenital malformations in growing fetuses.

The continually growing Zofran lawsuits were recently consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2657. The cases involved are being overseen by Judge F. Dennis Saylor IV in Boston, Massachusetts. As they await additional trial preparations, the attorneys of Monheit Law are helping to ensure that anyone who used Zofran while pregnant, and who subsequently gave birth to a child with defects, will be provided with the important opportunity to investigate their legal rights in full. These mothers, families, and children may be entitled to legal action and substantial compensation. Currently, Monheit Law is offering free legal consultations to qualified individuals, in order to help them seek justice.

To ask questions or request additional information, please contact Michael Monheit, Esq., lead attorney at Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60008424